Tonix Pharmaceuticals Holding (TNXP) Cash from Operations (2010 - 2026)

Tonix Pharmaceuticals Holding has reported Cash from Operations for 17 years, with the latest figure at -$42.2 million in Q2 2026.

• On a quarterly basis, Cash from Operations fell 184.79% year-over-year to -$42.2 million in Q2 2026; TTM through Jun 2026 was -$153.0 million, a 135.94% decrease from a year earlier, with the FY2025 full-year figure at -$99.8 million, down 63.88% from the prior year.
• Cash from Operations was -$42.2 million for Q2 2026 at Tonix Pharmaceuticals Holding, roughly flat from -$42.3 million in the prior quarter.
• The five-year high for Cash from Operations was -$9.9 million in Q2 2024, with the low at -$42.3 million in Q1 2026.
• Average Cash from Operations over 5 years is -$24.7 million, with a median of -$22.9 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2026: Cash from Operations jumped 57.55% in 2024, then slumped 184.79% in 2026.
• Over 5 years, Cash from Operations stood at -$22.3 million in 2022, then dropped by 0.17% to -$22.3 million in 2023, then surged by 34.51% to -$14.6 million in 2024, then plunged by 171.02% to -$39.6 million in 2025, then dropped by 6.54% to -$42.2 million in 2026.
• The last three Cash from Operations figures came in at -$42.2 million (Q2 2026), -$42.3 million (Q1 2026), and -$39.6 million (Q4 2025), per Business Quant data.